Financial PerformanceNeuroBo reported 3Q24 results with a net loss of ($5.7M) and ended the period with $21.7M in cash on the balance sheet which the company expects to provide runway into 3Q25.
Market PerceptionShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space.
Research And DevelopmentDespite the small sample size and short study duration, the Phase 2a study successfully confirmed DA-1241’s anti-inflammatory effects.